Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Jasper Therapeutics Inc. (JSPR)

Jasper Therapeutics Inc. (JSPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 85,506
  • Shares Outstanding, K 15,001
  • Annual Sales, $ 0 K
  • Annual Income, $ -64,470 K
  • EBIT $ -69 M
  • EBITDA $ -68 M
  • 60-Month Beta 2.18
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.05

Options Overview Details

View History
  • Implied Volatility 131.63% ( +12.74%)
  • Historical Volatility 274.46%
  • IV Percentile 76%
  • IV Rank 31.87%
  • IV High 306.55% on 01/07/25
  • IV Low 49.82% on 10/10/24
  • Put/Call Vol Ratio 0.04
  • Today's Volume 113
  • Volume Avg (30-Day) 1,502
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 3,789
  • Open Int (30-Day) 10,005

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.27
  • Number of Estimates 5
  • High Estimate -1.11
  • Low Estimate -1.36
  • Prior Year -1.50
  • Growth Rate Est. (year over year) +15.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.25 +8.57%
on 01/17/25
22.99 -75.20%
on 12/27/24
-16.01 (-73.74%)
since 12/24/24
3-Month
5.25 +8.57%
on 01/17/25
26.05 -78.12%
on 12/03/24
-14.20 (-71.36%)
since 10/24/24
52-Week
5.25 +8.57%
on 01/17/25
31.01 -81.62%
on 04/01/24
-5.10 (-47.22%)
since 01/24/24

Most Recent Stories

More News
Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

JSPR : 5.70 (-2.90%)
Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

JSPR : 5.70 (-2.90%)
Insider Sale: Chief Operating Officer of $JSPR (JSPR) Sells 900 Shares

Jeetinder Singh Mahal, the Chief Operating Officer of $JSPR ($JSPR), sold 900 shares of the company on 12-12-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

JSPR : 5.70 (-2.90%)
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab for Allergic Asthma

Jasper Therapeutics initiates Phase 1b/2a study of briquilimab for allergic asthma, targeting mast cell-driven diseases.Quiver AI SummaryJasper Therapeutics, Inc. has announced the dosing of the first...

JSPR : 5.70 (-2.90%)
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

JSPR : 5.70 (-2.90%)
Jasper Therapeutics to Participate at Upcoming Investor Conferences

JSPR : 5.70 (-2.90%)
Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

JSPR : 5.70 (-2.90%)
Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

JSPR : 5.70 (-2.90%)
Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria

JSPR : 5.70 (-2.90%)
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

JSPR : 5.70 (-2.90%)

Business Summary

Jasper Therapeutics Inc., a biotechnology company focused on hematopoietic cell transplant therapies. Jasper Therapeutics Inc., formerly known as Amplitude Healthcare Acquisition Corporation, is based in REDWOOD CITY, Calif.

See More

Key Turning Points

3rd Resistance Point 6.24
2nd Resistance Point 6.13
1st Resistance Point 5.91
Last Price 5.70
1st Support Level 5.58
2nd Support Level 5.47
3rd Support Level 5.25

See More

52-Week High 31.01
Fibonacci 61.8% 21.17
Fibonacci 50% 18.13
Fibonacci 38.2% 15.09
Last Price 5.70
52-Week Low 5.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar